Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia
30 mars 2022 06h30 HE
|
Design Therapeutics, Inc.
Topline Data from Phase 1 Trial Expected in the Second Half of 2022 DT-216 Granted FDA Fast Track Designation for Patients with Friedreich Ataxia CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE)...
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
10 mars 2022 16h02 HE
|
Design Therapeutics, Inc.
Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the...
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
09 mars 2022 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that...
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
28 févr. 2022 16h05 HE
|
Design Therapeutics, Inc.
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline Data from Phase 1 Trial Expected in the Second Half of 2022 CARLSBAD, Calif., Feb. 28, 2022 (GLOBE...
Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
10 févr. 2022 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that...
Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
01 févr. 2022 16h05 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that...
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results
09 nov. 2021 16h05 HE
|
Design Therapeutics, Inc.
Clinical Initiation of Lead GeneTACTM Program for Friedreich Ataxia On-track for the First Half of 2022 CARLSBAD, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN),...
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
08 sept. 2021 06h30 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing small molecule treatments for degenerative genetic disorders, today...
Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results
09 août 2021 16h05 HE
|
Design Therapeutics, Inc.
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon,...
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
07 juin 2021 16h10 HE
|
Design Therapeutics, Inc.
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that...